Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
By M. Topp, N. Gökbuget, A. Stein, G. Zugmaier, S. O'brien, R. Bargou, H. Dombret, A. Fielding, L. Heffner, R. Larson and 15 more. The Lancet Oncology, 2015
1,126 citations recorded by the source corpus.
Subfields: Oncology, Public Health, Environmental and Occupational Health, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/2e4c4aa1a009313c14f1979312837a98af4b1848
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, neutral): “Blinatumomab, a bi-specific antibody that both targets CD19 and activates T lymphocytes, can cause both a global encephalopathy aswell asmore localized defects such as aphasia, tremor, ataxia, hemiparesis, and cranial nerve palsies.(59,60) The neurologic toxicities associated with anti-CD19 CAR T ce”
- Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (2017, background): “094 40–60 years 42 (66) 8 (13) 14 (22) 64 >60 years 27 (64) 7 (17) 8 (19) 42 Sex, n (%) Male 59 (63) 17 (18) 17 (18) 93 0.”
- The making of bispecific antibodies (2017, methodology): “The antibody is thus administered as continuous intravenous infusion at a constant flow rate with a portable pump in repeated four-week cycles.(57)”
- CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017, positive): “Blinatumomab, a CD19xCD3 bispecific antibody, mediates impressive effects in patients with overt 8,9 and minimal residual disease (MRD) levels of B-ALL 10 .”
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (2021, background): “High-grade B-cell lymphoma, including rearrangement of MYC with BCL2 or BCL6 or both 31 (17) 25 (14) 56 (16)”
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. (2018, methodology): “Similar neurologic events have been observed with other CD19-directed therapies,(27-29) in other T-cell-activating studies,(30) and in blinatumomab studies in relapsed/refractory ALL and non-Hodgkin’s lymphoma.(18,22,24) The pathogenesis of neurologic events is poorly understood and does not seem to”
- Cytokine release syndrome (2018, background): “…to prevent the occurrence of severe CRS. Based on the insight gained from the first clinical trials of blinatumomab a prophylactic protocol consisting of cytoreduction, dose adjustment, and premedication with corticosteroids has been devised, that resulted in a reduced incidence of severe CRS [68].”